Identification of significant prognostic risk markers for pancreatic ductal adenocarcinoma: a bioinformatic analysis

被引:1
|
作者
Zhang, Zhipeng [1 ]
Sun, Weijia [2 ]
Zeng, Zhijun [1 ]
Lu, Yebin [2 ]
机构
[1] Cent South Univ, Xiangya Hosp, Dept Geriatr Surg, Changsha 410008, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Pancreatobiliary Surg, Changsha 410008, Peoples R China
关键词
Pancreatic ductal adenocarcinoma; Bioinformatics; Prognostic markers; Cancer Genome Atlas; CANCER; TARGET; METASTASIS; INVASION; MUTATION; GENES; CELLS; FZD8; P53;
D O I
10.18388/abp.2020_5758
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Objective: This study aimed to identify novel prognostic biomarkers of pancreatic ductal adenocarcinoma (PDAC) using bioinformatics analyzes. Methods: Clinical information, microRNAs (miRNAs), and genes expression profile data from PDAC cases were downloaded from the Cancer Genome Atlas (TCGA) database. The potential prognostic risk miRNAs and genes were screened using the Elastic Net Cox proportional risk regression hazards (EN-COX) model. The receiver operating characteristic (ROC) curve and the Kaplan-Meier (KM) curve were used to identify miRNAs and genes of significant prognostic risk. Furthermore, significant prognostic risk miRNAs were functional enrichment analyses based on their target genes. Furthermore, the survival analyzes of the hub genes were validated through OncoLnc. Results: Complete clinical records and expression data of 797 miRNAs and 19969 genes from 137 PDAC cases were obtained, of which 59 potential prognostic risk factors, including 54 genes and 5 miRNAs, were selected by EN-COX analyzes. A total of 17 significant prognostic risk markers were identified (all P<0.05), including 16 genes and 1 miRNA ( miRNA-125a). The miRNA-125a target genes were found in the MiRWalk database and the function enrichment analyzes were performed in the the DA-VID website. Furthermore, according to data from the Oncomine and Human Protein Atlas (HPA) databases, the mRNA and protein level of frizzled class receptor 8 (FZD8) were overexpressed in pancreatic cancer tissues compared to the corresponding noncancer normal tissues (P<0.001). However, both glutathione Stransferase mu 4 (GSTM4) and inducible T cell costimulator ligand (ICOSLG) were negatively regulated in tissues of pancreatic cancer tissues (P<0.001). Finally, survival analysis was used to validate these factors by the OncoLnc database, and the results revealed that overexpression of ICOSLG was associated with a better prognosis (P=0.025). Conclusions: This study showed that the expression levels of FZD8, GSTM4 and ICOSLG were significantly different between PDAC and non-tumor tissues, especially ICOSLG, which could be a prognostic indicator and therapeutic target for PDAC.
引用
收藏
页码:327 / 333
页数:7
相关论文
共 50 条
  • [21] Identification of significant genes as prognostic markers and potential tumor suppressors in lung adenocarcinoma via bioinformatical analysis
    Lu, Mingze
    Fan, Xiaowen
    Liao, Weilin
    Li, Yijiao
    Ma, Lijie
    Yuan, Mu
    Gu, Rui
    Wei, Zhengdao
    Wang, Chao
    Zhang, Hua
    BMC CANCER, 2021, 21 (01)
  • [22] Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma
    Liu, Wen-Jing
    Zhou, Li
    Liang, Zhi-Yong
    Zhou, Wei-Xun
    You, Lei
    Zhang, Tai-Ping
    Zhao, Yu-Pei
    CHINESE MEDICAL JOURNAL, 2018, 131 (24) : 2947 - +
  • [23] Identification of Prognostic Biomarkers and Drugs Targeting Them in Colon Adenocarcinoma: A Bioinformatic Analysis
    Dong, Shu
    Ding, Zhimin
    Zhang, Hao
    Chen, Qiwen
    INTEGRATIVE CANCER THERAPIES, 2019, 18
  • [24] MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm
    Xue, Yue
    Abou Tayoun, Ahmad N.
    Abo, Kristine M.
    Pipas, J. Marc
    Gordon, Stuart R.
    Gardner, Timothy B.
    Barth, Richard J., Jr.
    Suriawinata, Arief A.
    Tsongalis, Gregory J.
    CANCER GENETICS, 2013, 206 (06) : 217 - 221
  • [25] Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma
    Kandimalla, Raju
    Shimura, Tadanobu
    Mallik, Saurav
    Sonohara, Fuminori
    Tsai, Susan
    Evans, Douglas B.
    Kim, Song Cheol
    Baba, Hideo
    Kodera, Yasuhiro
    Von Hoff, Daniel
    Chen, Xi
    Goel, Ajay
    ANNALS OF SURGERY, 2022, 275 (01) : E229 - E237
  • [26] Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma
    Iuga, Cristina
    Seicean, Andrada
    Iancu, Cornel
    Buiga, Rares
    Sappa, Praveen K.
    Voelker, Uwe
    Hammer, Elke
    PROTEOMICS, 2014, 14 (7-8) : 945 - 955
  • [27] Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma
    Li, Qing
    Wang, Hao
    Zogopoulos, George
    Shao, Qin
    Dong, Kun
    Lv, Fudong
    Nwilati, Karam
    Gui, Xian-Yong
    Cuggia, Adeline
    Liu, Jun-Li
    Gao, Zu-Hua
    ONCOTARGET, 2016, 7 (47) : 77838 - 77853
  • [28] Establishment of Three Gene Prognostic Markers in Pancreatic Ductal Adenocarcinoma Using Machine Learning Approach
    Pragya, Pragya
    Govarthan, Praveen Kumar
    Nayak, Malay
    Mukherjee, Sudip
    Ronickom, Jac Fredo Agastinose
    JOURNAL OF MEDICAL AND BIOLOGICAL ENGINEERING, 2024, 44 (03) : 357 - 365
  • [29] Prognostic significance of WNT signaling in pancreatic ductal adenocarcinoma
    Nakamoto, Mitsuhiro
    Matsuyama, Atsuji
    Shiba, Eisuke
    Shibuya, Ryo
    Kasai, Takahiko
    Yamaguchi, Koji
    Hisaoka, Masanori
    VIRCHOWS ARCHIV, 2014, 465 (04) : 401 - 408
  • [30] Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma
    Petrova, Ekaterina
    Zielinski, Verena
    Bolm, Louisa
    Schreiber, Cleopatra
    Knief, Juliana
    Thorns, Christoph
    Bronsert, Peter
    Timme-Bronsert, Sylvia
    Bausch, Dirk
    Perner, Sven
    Keck, Tobias
    Wellner, Ulrich
    VIRCHOWS ARCHIV, 2020, 476 (04) : 561 - 568